New Phase 3 trial data finds a single shot of Regeneron's COVID-19 antibody cocktail was able to prevent symptomatic COVID-19 among people exposed to the virus, the company said Monday.
After 29 days, 11 people who received a single 1,200 mg dose of the treatment developed symptomatic COVID-19; 59 people who received a placebo developed symptomatic COVID-19. The drug provided 72% protection against symptomatic infections in the first week and 93% protection in subsequent weeks, Regeneron said. The data has not yet been peer reviewed or published.
Adverse events occurred in 20% of patients who received the antibody drug and 29% of those who received a placebo, Regeneron said. None of the participants who received the drug were hospitalized or went to the ER because of COVID-19 over the course of 29 days; four in the placebo group did so. None of the four deaths in the trial -- two among those who received the drug and two who received a placebo -- were due to COVID-19 or the drug.
investing with maria D bate was the best thing that have ever happened to me cause I ear u p to $5000 with $400 through forex trading she's the best I know of , after I was scammed , thanks very much mam . well if you are interested click and message her 👇👇👇 mariadbates2